
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

- Preliminary Proxy Statement
 Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
 Definitive Proxy Statement
 Definitive Additional Materials
 Soliciting Material Pursuant to §240.14a-12

ALKERMES PLC


(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check all boxes that apply)

- No fee required
 Fee paid previously with preliminary materials
 Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11
-

On June 21, 2023, Alkermes plc (the “Company”) updated the website (<https://www.alkermesvalue.com/>) it launched in connection with the Company’s 2023 annual general meeting of shareholders. A copy of the updated pages on the website can be found below:



A Strong Foundation Value for Stakeholders

Momentum for Long-Term Success

Alkermes' Board of Directors (the Board) and management team have been focused on positioning the company for long-term growth and value creation. Alkermes' strong recent performance is a direct result of its execution against three clear strategic priorities: **growing its portfolio of proprietary commercial products, advancing its development pipeline and driving profitability for the benefit of its shareholders.** These priorities are grounded in a culture of responsibility throughout the organization – responsibility to patients, employees and communities – and the Company's commitment to strong corporate governance practices.

Shareholder Materials for our 2023 Annual Meeting

Use these links to access shareholder materials and other information that may be helpful in advance of our 2023 Annual General Meeting of Shareholders (the Annual Meeting).

Shareholder Letters

Important communications from the Board

[View Letters](#)

Shareholder Presentations

Helpful information for our shareholders

[View Presentations](#)

Press Releases

Selection of Alkermes news, including our recent financial results

[View Press Releases](#)

SEC Filings

Click to access our proxy materials

[View Filings](#)

Your vote at the Annual Meeting on June 29, 2023 is very important. **We urge all shareholders to vote "FOR" the election of all seven of the Board's director nominees and "FOR" all other proposals in our proxy statement using the WHITE proxy card sent to you.** The Board recommends that you do not mark any votes with respect to the director nominees of Sarissa Capital Offshore Master Fund LP (together with its affiliates and associates, Sarissa).

You can vote in one of three easy ways: by internet, by telephone or by mail.

[Learn more](#)

Board of Directors

Richard F. Pops Chairman and CEO	Emily Peterson Alva	Shane M. Cooke
David A. Daglio	Richard B. Gaynor, M.D.	Cato T. Laurencin, M.D., Ph.D.
Brian P. McKeon	Nancy L. Snyderman, M.D.	Andy Wilson
Christopher I. Wright, M.D., Ph.D.	Nancy J. Wysenski	

Alkermes has an active, skilled and highly experienced board of directors that is heavily engaged in and supportive of the Company and its strategy. The Board has a strong and diverse set of backgrounds, skills and experiences relevant to our industry and our operations.

[View Board skills matrix](#)

Creating Value for Shareholders

The Board and Alkermes' management team have been keenly focused on the following objectives to best position Alkermes for long-term growth and value creation:


- Execute on the Company's Value Enhancement Plan, which is comprised of a number of initiatives, including Board refreshment, evaluation of strategic opportunities and establishment of long-term profitability targets.
- Drive operational efficiency and calibrate Alkermes' cost structure to appropriately support the Company's strategic priorities and growth opportunities.
- Work toward the planned separation of the Company's oncology business and neuroscience business, which the Board believes will unlock shareholder value by enhancing the performance of both businesses and accelerating profitability for the neuroscience business.

Since the Company's December 2020 announcement of its Value Enhancement Plan, Alkermes' share price has increased by 49%, and Alkermes has outperformed its peers¹ by 61%, the XBI biotech index by 83% and the NBI biotech index by 56%². Alkermes' total shareholder return (TSR) has also outperformed its peers and the XBI and NBI over various other timeframes, including on a 1-year and 3-year trailing basis.

Alkermes has also appointed seven new independent directors to the Board, while five longer-serving directors have retired. The newly appointed directors include a director designated by Sarissa in November 2021 (Cato T. Laurencin, M.D., Ph.D.), a



director designated by Elliott Advisors (UK) (Elliott) in May 2021 (Emily Peterson Alva), and two directors appointed with the support of Elliott in December 2020 (David A. Daglio and Brian P. McKeon) – all of whom continue to serve on the Board.



Shareholder Presentations

Recent Relevant Alkermes Presentations

June 21, 2023

[Correcting ISS' Flawed Financial Analysis](#)

June 7, 2023

[Executing on our Strategy to Drive Shareholder Value](#)



Contacts

Media

mediainfo@alkermes.com

Investor Inquiries

investor_relations@alkermes.com



Recent Relevant Alkermes News

Recent Relevant Alkermes News

6/21/23

Independent Proxy Advisory Firm Glass Lewis Recommends Alkermes Shareholders Vote “FOR” All Seven of the Company’s Highly Qualified Director Nominees

6/20/23

Independent Proxy Advisory Firm ISS Recommends Alkermes Shareholders Vote Against Sarissa Employees’ Election to Alkermes Board

6/13/23

Alkermes Issues Letter to Shareholders Highlighting Skills and Experience of Refreshed Board of Directors

6/8/23

Alkermes Publishes Investor Presentation Detailing Company’s Transformation and Value Creation

6/6/23

Alkermes Announces Final Award in Janssen Pharmaceutica Arbitration and Provides Updated Financial Expectations

6/1/23

Alkermes Appoints Caroline J. Loew, Ph.D., as Chief Executive Officer Designate of Mural Oncology plc

5/25/23

Alkermes Files Definitive Proxy Statement and Issues Letter to Shareholders Detailing Business Execution That Has Driven Strong Performance and Delivered Shareholder Value

5/8/23

Alkermes Files Preliminary Proxy Statement and Provides Update on Annual Director Nomination Process

4/26/23

Alkermes plc Reports First Quarter 2023 Financial Results

4/25/23

Alkermes Announces Second Interim Award in Janssen Pharmaceutica Arbitration

4/18/23

Alkermes Announces Submission of Confidential Draft Form 10 Registration Statement for Planned Separation of Oncology Business

2/16/23

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2022 and Provides Financial Expectations for 2023

11/2/22

Alkermes plc Reports Third Quarter 2022 Financial Results

11/2/22

Alkermes plc Announces Intent to Separate Oncology Business

7/27/22

Alkermes plc Reports Second Quarter 2022 Financial Results

7/7/22

Alkermes Announces Results of Annual General Meeting of Shareholders

5/26/22

Alkermes Announces Continued Board Refreshment, Including the Appointment of Christopher I. Wright, M.D., Ph.D. to its Board of Directors

4/27/22

Alkermes plc Reports First Quarter 2022 Financial Results

4/19/22

Alkermes Commences Arbitration Related to License Agreements with Janssen Pharmaceutica

2/16/22

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2021 and Provides Financial Expectations for 2022

11/19/21

Alkermes Announces the Appointment of Cato T. Laurencin, M.D., Ph.D. to its Board of Directors

5/20/21

Alkermes Announces the Appointment of Emily Peterson Alva to its Board of Directors

4/30/21

Alkermes Announces Agreement with Sarissa Capital

3/25/21

Alkermes Investor Day to Focus on Scientific Progress and Value Creation Strategy

1/6/21

Alkermes Announces Updates to Executive Leadership Team

12/10/20

Alkermes Announces Strategic Value Enhancement Plan and Continued Board Refreshment

[Click here to access all Alkermes press releases](#)



[Contact Us](#)

[Terms of Use](#)

[Privacy Policy](#)

[Sitemap](#)



Sitemap

Pages

- [Home](#)
- [Shareholder Materials](#)
 - [Shareholder Letters](#)
 - [Shareholder Presentations](#)
 - [Recent Relevant Alkermes News](#)
 - [SEC Filings](#)
- [Board of Directors](#)
- [How to Vote](#)
- [Contact Us](#)
- [Terms of Use](#)
- [Privacy Policy](#)
- [Sitemap](#)